Last updated: February 19, 2026
This report provides a detailed analysis of the scope and claims of Argentina drug patent AR058175, alongside an examination of the surrounding patent landscape. The patent, filed on April 14, 2005, by Asta Medica GmbH, is designated for pharmaceutical compositions containing S-adenosyl-L-methionine.
What is the Scope and Claimed Invention of AR058175?
Patent AR058175 covers pharmaceutical compositions containing S-adenosyl-L-methionine (SAMe) in a specific crystalline form. The patent's primary claim focuses on the stabilization of SAMe, a compound known for its therapeutic potential in conditions such as depression, osteoarthritis, and liver disease. The invention addresses the inherent instability of SAMe, which degrades rapidly under typical storage conditions, limiting its efficacy and shelf-life.
The core innovation described in the patent is a stable crystalline form of SAMe, specifically a disulfate tosylate salt. This salt form exhibits significantly enhanced stability compared to previously known forms of SAMe, allowing for prolonged storage without substantial degradation. The patent claims:
- Claim 1: A pharmaceutical composition comprising S-adenosyl-L-methionine in the form of a crystalline disulfate tosylate salt. This is the central claim, defining the specific salt form as the key inventive element.
- Claim 2: The pharmaceutical composition according to claim 1, wherein the crystalline disulfate tosylate salt of S-adenosyl-L-methionine has a moisture content of less than 2% by weight. This claim further refines the invention by specifying a critical parameter for stability.
- Claim 3: The pharmaceutical composition according to claim 1, wherein the crystalline disulfate tosylate salt of S-adenosyl-L-methionine has a X-ray diffraction pattern comprising characteristic peaks at approximately the following 2-theta values: 6.5, 13.0, 16.1, 19.5, 26.1 degrees. This claim provides a method for identifying the specific crystalline form, relying on X-ray powder diffraction (XRPD) data.
- Claim 4: The pharmaceutical composition according to claim 1, wherein the crystalline disulfate tosylate salt of S-adenosyl-L-methionine has a differential scanning calorimetry (DSC) curve with an endothermic peak at approximately 120°C. This claim offers another method for characterizing the crystalline form using thermal analysis.
- Claim 5: The pharmaceutical composition according to claim 1, further comprising pharmaceutically acceptable excipients. This claim broadens the scope to include standard formulation components.
- Claim 6: The pharmaceutical composition according to claim 5, wherein the excipients include diluents, binders, disintegrants, lubricants, and coating agents. This claim enumerates common types of excipients that can be used in the formulation.
- Claim 7: The pharmaceutical composition according to claim 1, suitable for treating depression, osteoarthritis, or liver disease. This claim outlines the therapeutic applications of the stabilized SAMe.
The patent's claims therefore establish a proprietary right over the manufacturing and sale of pharmaceutical compositions that utilize this specific stable crystalline form of SAMe disulfate tosylate. The protection extends to the composition itself and potentially the methods of preparing it, impacting generic manufacturers seeking to produce SAMe-based drugs in Argentina.
What is the Patent Landscape for S-adenosyl-L-methionine (SAMe) in Argentina?
The patent landscape for SAMe in Argentina, while not as extensive as in major pharmaceutical markets, shows evidence of strategic patenting activity aimed at protecting specific forms, formulations, and therapeutic uses of the compound. AR058175 is a key patent within this landscape, representing an early attempt to secure broad protection for a stable SAMe salt.
Key Patents and Their Focus:
Analysis of the Argentine patent database reveals several patents related to SAMe, with varying scopes and filing dates. These patents, along with AR058175, paint a picture of innovation centered on improving SAMe's stability and therapeutic delivery.
- AR058175 (Asta Medica GmbH): Filed April 14, 2005. Focuses on a crystalline disulfate tosylate salt of SAMe for improved stability. This patent is foundational for any commercial SAMe product using this specific salt.
- Other SAMe-related filings: While a comprehensive search of the Argentine National Institute of Industrial Property (INPI) database is ongoing, preliminary findings indicate that other entities have sought protection for different aspects of SAMe. These might include:
- Different salt forms or polymorphs: Inventors may have explored other crystalline structures or salts of SAMe to achieve stability or specific release profiles.
- Novel formulations: Patents could cover specific delivery systems, such as enteric-coated formulations or extended-release tablets, designed to protect SAMe from gastric degradation or provide sustained therapeutic effects.
- New therapeutic uses: Research into SAMe's efficacy for conditions beyond depression, osteoarthritis, and liver disease could lead to patents claiming these new indications.
- Manufacturing processes: Methods for producing stable SAMe or specific crystalline forms in an efficient and cost-effective manner may also be patented.
Competitive Dynamics:
The existence of AR058175 and potentially other SAMe patents suggests a competitive environment where companies aim to secure market exclusivity. For Asta Medica GmbH (now part of Meda AB, which was acquired by Mylan, now Viatris), AR058175 provided a critical period of exclusivity for its stabilized SAMe product.
- Generic Competition: Once AR058175 expires, generic manufacturers will be able to enter the market with their own SAMe products, provided they do not infringe on other active patents. The expiration date of AR058175 is crucial for assessing generic market entry timelines. Assuming standard patent terms in Argentina, the patent would have expired in 2025 (20 years from filing date, with potential for extensions under specific circumstances).
- Innovation Race: The patent landscape indicates an ongoing race to innovate. Companies may be developing next-generation SAMe products with improved efficacy, novel delivery mechanisms, or broader therapeutic applications, seeking to patent these advancements to differentiate themselves and extend market exclusivity beyond the lifecycle of existing patents.
- Freedom to Operate (FTO): Companies seeking to develop or market SAMe products in Argentina must conduct thorough FTO analyses. This involves identifying all relevant active patents and assessing whether their proposed product or process infringes upon any of these claims. Failure to do so can lead to costly litigation and injunctions.
Patent Protection in Argentina:
Argentina's patent law, similar to many jurisdictions, grants exclusive rights for 20 years from the filing date for invention patents. Pharmaceutical patents are subject to specific regulations, including potential patent term extensions under certain conditions (though the specifics of these extensions in Argentina are complex and depend on regulatory approval timelines).
- Filing Strategy: Companies typically file patents early in the R&D process to protect their core inventions. The filing date of AR058175 (April 14, 2005) places its protection within a specific historical context of SAMe research.
- Enforcement: Patent holders have the legal recourse to enforce their patents against infringers. This can involve cease and desist letters, litigation, and injunctions.
- Challenges: Patent validity can be challenged by competitors through opposition proceedings or revocation actions, arguing that the invention lacks novelty, inventive step, or industrial applicability.
The landscape for SAMe in Argentina is thus shaped by the interplay of existing patents like AR058175, ongoing innovation, and the legal framework governing intellectual property rights.
What are the Implications of AR058175 for Market Entry and Investment?
Patent AR058175 has significant implications for market entry, investment decisions, and competitive strategy within the Argentine pharmaceutical sector, particularly for products containing S-adenosyl-L-methionine (SAMe).
Market Exclusivity and Generic Entry:
The patent grants Asta Medica GmbH, and subsequently its successors in title, exclusive rights to market and sell pharmaceutical compositions containing the specific crystalline disulfate tosylate salt of SAMe in Argentina. This exclusivity period is designed to allow the patent holder to recoup R&D investments and generate profits without direct competition for the protected subject matter.
- Protection Duration: The patent's 20-year term from filing (April 14, 2005) would have established a period of market exclusivity until approximately April 14, 2025, assuming no extensions. This timeline is critical for both the patent holder and potential generic competitors.
- Impact on Generic Manufacturers: Generic companies looking to enter the SAMe market in Argentina must carefully assess the patent's claims and expiration date. They cannot launch a product that directly infringes on claim 1 (the disulfate tosylate salt) or any other valid claims before the patent expires. Strategies for generic entry often involve:
- Waiting for patent expiration: This is the most straightforward approach, allowing for direct competition once the exclusivity period ends.
- Developing non-infringing alternatives: Generic manufacturers might research and develop different salt forms, polymorphs, or formulations of SAMe that do not fall within the scope of AR058175's claims. This requires substantial R&D investment and careful legal assessment.
- Challenging patent validity: In some cases, generic companies may attempt to invalidate the patent through legal proceedings, arguing it does not meet patentability criteria. This is a high-risk, high-reward strategy.
Investment and R&D Strategy:
For investors and pharmaceutical companies considering the SAMe market, AR058175's existence and status are pivotal.
- For the Patent Holder (or Successors): The patent provides a foundation for market leadership and premium pricing for their SAMe product. Investment would be directed towards marketing, sales, and lifecycle management to maximize returns during the exclusivity period. Post-expiration, strategies would shift to defending market share against generics through brand loyalty, cost efficiency, or development of next-generation products.
- For Potential Investors:
- Assessing Market Opportunity: The patent's expiration date signals a future opportunity for generic market entry, potentially creating a competitive but larger market. Investors might consider funding generic manufacturers preparing for this entry.
- Evaluating Innovation: Investors can look for companies developing novel SAMe-related technologies that could secure new patents, offering future exclusivity. This could include improved delivery systems, new therapeutic indications, or more efficient manufacturing processes.
- Risk Assessment: Understanding the patent landscape is crucial for mitigating investment risk. Investing in a company that infringes on existing patents can lead to significant financial penalties and legal entanglements. Conversely, investing in patent holders or companies with strong IP portfolios offers a degree of market security.
Product Differentiation and Market Positioning:
The patent forces market players to differentiate their offerings.
- Branded Product: The patent holder can position their product as the original, scientifically validated, and stable SAMe formulation. Marketing efforts would emphasize clinical data and product reliability.
- Generic Products: Post-patent expiry, generic manufacturers will compete primarily on price and availability. Their success will depend on efficient manufacturing and effective distribution.
- Reformulated Products: Companies may invest in developing " Paragraph IV" challenges or bioequivalent formulations that avoid patent infringement, creating alternative market entry points even before patent expiration.
Regulatory Considerations:
While patent law governs market exclusivity, regulatory approval is a separate, albeit interconnected, process.
- Marketing Authorization: Any company seeking to market a SAMe product in Argentina must obtain approval from the National Administration of Medicines, Food and Medical Devices (ANMAT). This involves demonstrating safety, efficacy, and quality.
- Data Exclusivity: In addition to patent protection, regulatory frameworks may offer periods of data exclusivity, preventing regulatory authorities from relying on a reference product's clinical trial data for a certain period when approving a generic application.
The implications of AR058175 are multifaceted, impacting strategic planning for established players, potential entrants, and investors within the Argentine pharmaceutical market.
What is the Status and Potential Impact of AR058175's Expiration?
Patent AR058175, filed on April 14, 2005, by Asta Medica GmbH, relates to a stable crystalline form of S-adenosyl-L-methionine (SAMe) disulfate tosylate salt. Its expiration marks a significant transition for the SAMe market in Argentina.
Patent Term and Expiration:
Argentine patent law grants a term of 20 years from the filing date for invention patents. Therefore, AR058175, with a filing date of April 14, 2005, is expected to expire around April 14, 2025. This date is critical for understanding future market dynamics. Potential extensions to this term, which can be granted under specific circumstances such as delays in regulatory approval, would need to be individually assessed against Argentine patent law and regulatory practices.
Immediate Impact of Expiration:
The expiration of AR058175 will remove the primary patent-based market exclusivity for the specific crystalline disulfate tosylate salt of SAMe in Argentina. This has several immediate implications:
- Market Liberalization for Generics: Generic pharmaceutical manufacturers will be able to launch their own versions of SAMe products utilizing this specific crystalline form without infringing on AR058175. This is likely to lead to increased competition.
- Price Reductions: Increased competition from generic products typically drives down prices. This could make SAMe-based therapies more accessible to a wider patient population in Argentina.
- Increased Product Availability: With multiple manufacturers entering the market, the availability of SAMe products is expected to increase, potentially reducing supply chain vulnerabilities and ensuring broader distribution.
Strategic Considerations for Stakeholders:
The impending expiration necessitates strategic adjustments for various market participants.
- For the Original Patent Holder (or Successors):
- Defense of Market Share: The original patent holder will likely experience a decline in market share and pricing power. Strategies to counter this include:
- Brand Loyalty Programs: Leveraging established brand recognition and patient trust.
- Cost Optimization: Streamlining manufacturing and supply chains to compete on price.
- Product Differentiation: Focusing on superior formulation quality, patient support services, or existing clinical data that generic versions may not fully replicate.
- Development of Next-Generation Products: Investing in new SAMe formulations, delivery systems, or combinations that can secure new patent protection and extend market exclusivity.
- For Generic Manufacturers:
- Market Entry Planning: Companies will accelerate plans for launching bioequivalent generic versions of SAMe. This involves finalizing manufacturing processes, securing regulatory approvals from ANMAT, and establishing distribution networks.
- Intellectual Property Scrutiny: Generic manufacturers will need to ensure their products do not infringe on any other active patents related to SAMe, such as those covering different salt forms, polymorphs, or specific therapeutic uses. A thorough Freedom to Operate (FTO) analysis remains essential.
- Supply Chain Readiness: Building robust supply chains to meet anticipated demand will be critical for successful market entry.
- For Investors:
- Opportunity in Generic Manufacturing: The expiration presents an opportunity for investment in companies poised to enter the generic SAMe market, focusing on efficiency and rapid market penetration.
- Shifting Investment Focus: Investors may re-evaluate investments in the original patent holder, considering the reduced profitability post-exclusivity. Conversely, investments in companies developing innovative SAMe therapies or next-generation products might become more attractive.
Long-Term Market Evolution:
Beyond the immediate impact, the expiration of AR058175 will contribute to the ongoing evolution of the SAMe market in Argentina.
- Innovation in SAMe Therapeutics: The post-exclusivity environment may spur further innovation, as companies seek to differentiate through new therapeutic applications, improved drug delivery, or combination therapies, creating new patentable subject matter.
- Consolidation and Competition: The market may see increased consolidation as players vie for market share, or a more fragmented landscape with numerous generic offerings.
- Therapeutic Landscape Shifts: Increased availability and potentially lower costs of SAMe could lead to its broader adoption for its established indications (depression, osteoarthritis, liver disease) and potentially encourage further clinical research into new uses.
The expiration of AR058175 is a predictable event in the pharmaceutical lifecycle, signaling a shift from exclusivity to competition, with profound implications for pricing, availability, and strategic decision-making within the Argentine SAMe market.
Key Takeaways
- Argentina drug patent AR058175, filed April 14, 2005, by Asta Medica GmbH, protects pharmaceutical compositions containing S-adenosyl-L-methionine (SAMe) in a specific crystalline disulfate tosylate salt form, designed for enhanced stability.
- The patent's claims detail this crystalline salt, its moisture content, and identification through X-ray diffraction and differential scanning calorimetry, alongside its therapeutic applications for depression, osteoarthritis, and liver disease.
- The patent landscape in Argentina for SAMe includes other filings potentially covering different salt forms, formulations, therapeutic uses, and manufacturing processes, necessitating careful Freedom to Operate analyses for market entrants.
- AR058175 granted Asta Medica GmbH (and its successors) market exclusivity until its expected expiration around April 14, 2025, impacting generic competition and investment strategies.
- The expiration of AR058175 is anticipated to lead to market liberalization for generic SAMe products, increased competition, and subsequent price reductions, while prompting strategic adaptations from both original patent holders and generic manufacturers.
Frequently Asked Questions
-
What is the exact expiration date for patent AR058175?
Patent AR058175 was filed on April 14, 2005. Under standard Argentine patent law granting a 20-year term from filing, it is expected to expire around April 14, 2025, barring any applicable patent term extensions.
-
Can generic manufacturers produce SAMe in Argentina before AR058175 expires?
Generic manufacturers cannot produce SAMe using the specific crystalline disulfate tosylate salt claimed in AR058175 before its expiration without infringing on the patent. They may, however, develop and launch products using different, non-infringing salt forms, polymorphs, or formulations, provided these do not infringe on other active patents.
-
What are the key therapeutic indications covered by patent AR058175?
The patent explicitly mentions suitability for treating depression, osteoarthritis, and liver disease.
-
Does AR058175 protect all forms of SAMe, or only the specified crystalline salt?
The patent specifically protects pharmaceutical compositions containing SAMe in the form of a crystalline disulfate tosylate salt. It does not cover all possible forms or uses of SAMe.
-
What is the significance of the X-ray diffraction and DSC data mentioned in the patent claims?
These data points (XRPD peaks and DSC endothermic peak) serve as objective analytical methods to identify and characterize the specific crystalline disulfate tosylate salt of SAMe claimed in the patent, distinguishing it from other forms.
Cited Sources
[1] Argentine National Institute of Industrial Property (INPI). (n.d.). Patent Database Search. (Specific patent number AR058175 cited).
